NCT01839019View on ClinicalTrials.gov

Safety and Tolerability Study With Single Ascending Doses of ODM-102

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

ODM-102

Single dose escalation

DRUG

Placebo for ODM-102

Single dose escalation

Trial Locations (1)

20520

Clinical Research Services Turku, CRST, Turku

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT01839019 - Safety and Tolerability Study With Single Ascending Doses of ODM-102 | Biotech Hunter | Biotech Hunter